Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease

被引:25
|
作者
Zhou, Cheng [1 ]
Wang, Linbo [2 ,3 ,4 ,5 ]
Cheng, Wei [2 ,3 ,4 ,5 ,6 ]
Lv, JinChao [2 ]
Guan, Xiaoujun [1 ]
Guo, Tao [1 ]
Wu, Jingjing [1 ]
Zhang, Wei [2 ,3 ,4 ,5 ]
Gao, Ting [7 ]
Liu, Xiaocao [1 ]
Bai, Xueqin [1 ]
Wu, Haoting [1 ]
Cao, Zhengye [1 ]
Gu, Luyan [7 ]
Chen, Jingwen [1 ]
Wen, Jiaqi [1 ]
Huang, Peiyu [1 ]
Xu, Xiaojun [1 ]
Zhang, Baorong [7 ]
Feng, Jianfeng [2 ,3 ,4 ,5 ,6 ]
Zhang, Minming [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Radiol, Hangzhou 310000, Peoples R China
[2] Fudan Univ, Inst Sci & Technol Brain Inspired Intelligence, Shanghai 200433, Peoples R China
[3] Fudan Univ, Key Lab Computat Neurosci & Brain Inspired Intelli, Minist Educ, Shanghai, Peoples R China
[4] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China
[5] Zhangjiang Fudan Int Innovat Ctr, Shanghai, Peoples R China
[6] Univ Warwick, Dept Comp Sci, Coventry CV4 7AL, England
[7] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310000, Peoples R China
基金
中国国家自然科学基金;
关键词
PROGRESSION MARKER; BIOMARKERS; PATHOLOGY; PATTERNS; SUBTYPES; ATROPHY;
D O I
10.1038/s41531-023-00556-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence suggests that Parkinson's disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique-Subtype and Stage Inference (SuStaIn) - to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
    Cheng Zhou
    Linbo Wang
    Wei Cheng
    JinChao Lv
    Xiaojun Guan
    Tao Guo
    Jingjing Wu
    Wei Zhang
    Ting Gao
    Xiaocao Liu
    Xueqin Bai
    Haoting Wu
    Zhengye Cao
    Luyan Gu
    Jingwen Chen
    Jiaqi Wen
    Peiyu Huang
    Xiaojun Xu
    Baorong Zhang
    Jianfeng Feng
    Minming Zhang
    npj Parkinson's Disease, 9
  • [2] Author Correction: Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
    Cheng Zhou
    Linbo Wang
    Wei Cheng
    JinChao Lv
    Xiaojun Guan
    Tao Guo
    Jingjing Wu
    Wei Zhang
    Ting Gao
    Xiaocao Liu
    Xueqin Bai
    Haoting Wu
    Zhengye Cao
    Luyan Gu
    Jingwen Chen
    Jiaqi Wen
    Peiyu Huang
    Xiaojun Xu
    Baorong Zhang
    Jianfeng Feng
    Minming Zhang
    npj Parkinson's Disease, 10
  • [3] Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease (vol 9, 111 , 2023)
    Zhou, Cheng
    Wang, Linbo
    Cheng, Wei
    Lv, Jinchao
    Guan, Xiaojun
    Guo, Tao
    Wu, Jingjing
    Zhang, Wei
    Gao, Ting
    Liu, Xiaocao
    Bai, Xueqin
    Wu, Haoting
    Cao, Zhengye
    Gu, Luyan
    Chen, Jingwen
    Wen, Jiaqi
    Huang, Peiyu
    Xu, Xiaojun
    Zhang, Baorong
    Feng, Jianfeng
    Zhang, Minming
    NPJ PARKINSONS DISEASE, 2024, 10 (01)
  • [4] Sequence of clinical and neurodegeneration events in Parkinson's disease progression
    Oxtoby, Neil P.
    Leyland, Louise-Ann
    Aksman, Leon M.
    Thomas, George E. C.
    Bunting, Emma L.
    Wijeratne, Peter A.
    Young, Alexandra L.
    Zarkali, Angelika
    Tan, Manuela M. X.
    Bremner, Fion D.
    Keane, Pearse A.
    Morris, Huw R.
    Schrag, Anette E.
    Alexander, Daniel C.
    Weil, Rimona S.
    BRAIN, 2021, 144 (03) : 975 - 988
  • [5] Alzheimer's disease and Parkinson's disease: Distinct entities or extremes of a spectrum of neurodegeneration?
    Perl, DP
    Olanow, CW
    Calne, D
    ANNALS OF NEUROLOGY, 1998, 44 (03) : S19 - S31
  • [6] Parkinson disease(s) Is "Parkin disease" a distinct clinical entity?
    Klein, Christine
    Lohmann, Katja
    NEUROLOGY, 2009, 72 (02) : 106 - 107
  • [7] Ageing, neurodegeneration and Parkinson's disease
    Hindle, John V.
    AGE AND AGEING, 2010, 39 (02) : 156 - 161
  • [8] Markers of Neurodegeneration in Parkinson’s Disease
    M. A. Nikitina
    V. M. Alifirova
    S. O. Borodina
    E. S. Koroleva
    Neurochemical Journal, 2023, 17 : 338 - 348
  • [9] Imaging neurodegeneration in Parkinson's disease
    Pavese, Nicola
    Brooks, David J.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2009, 1792 (07): : 722 - 729
  • [10] Glaucoma, Parkinson's disease and neurodegeneration
    Balci, Sevcan Yildiz
    Eraslan, Muhsin
    Temel, Ahmet
    MARMARA MEDICAL JOURNAL, 2015, 28 (01): : 8 - 12